KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得

Efficacy, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab intravenously administered to adults with active rheumatoid arthritis and an inadequate response to methotrexate: a phase 3, randomised study.

Hiroaki Matsuno, Ernest Choy, Paul Emery, Masato Okada, Roshan Dias, Károly Horvát-Karajz, Gordana Dancer, Yusuke Karibe, Suguru Masuda, Joachim Kiefer, Gerd R Burmester

EULAR Rheumatol Open 2(1) 155-165

PMID42370118
PMCIDPMC13292490
DOI10.1016/j.ero.2025.12.010
发表日期2026-06-29
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:图注未提示 KM 曲线;Figure 2:ROC 图;Figure 3:图注未提示 KM 曲线。
摘要

摘要

OBJECTIVES: This phase 3 study (jRCT2031220512) evaluated the equivalence in efficacy, and compared the serum concentration, pharmacodynamics, safety, and immunogenicity of proposed biosimilar RGB-19 and tocilizumab in adults with active rheumatoid arthritis (RA). METHODS: Participants were randomly assigned 1:1 to intravenous infusions of 8 mg/kg RGB-19 or tocilizumab every 4 weeks, with efficacy evaluated to week 52 and safety follow-up to week 54. The primary endpoint was the mean change from baseline (CfB) in Disease Activity Score based on 28 joints with erythrocyte sedimentation rate (DAS28-ESR), with equivalence determined if the 2-sided 95% CI for the pooled difference between groups was within the predefined equivalence margin (±0.6 at week 12). Secondary objectives were other efficacy indicators, serum drug concentration, pharmacodynamics, safety, and immunogenicity. RESULTS: In total, 368 participants were randomly assigned to treatment (RGB-19 N = 182; tocilizumab N = 186). At week 12, the difference in mean DAS28-ESR CfB between groups (RGB-19 n = 173; tocilizumab n = 181) was -0.21 (95% CI: -0.43, 0.02; within the equivalence margin). All other efficacy indicators and serum drug concentration values were similar between groups up to week 52. Median absolute neutrophil count, C-reactive protein, and soluble interleukin-6 receptor values were similar between groups to week 52. Safety profiles were similar, with a similar incidence of treatment-emergent adverse events and adverse drug reactions to week 54. The incidence of treatment-emergent antidrug and neutralising antibodies was similarly low in both groups. CONCLUSIONS: This study demonstrated equivalent efficacy, and similar safety and immunogenicity, of RGB-19 and reference tocilizumab for participants with active RA.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Participant disposition flow chart. AEs, adverse events.
非 KM Figure
Figure 2Figure 2 DAS28-ESR score and mean change from baseline from week 8 to week 52 (FAS). Error bars depict the 95% CI; a includes measurements after occurrence of intercurrent events; b for 1 participant ESR (mm/h) was not measured at week 24, but the other components were measured. Therefore, DAS28-ESR could not be calculated and was missing for this participant. CfB, change from baseline; CI, confidence interval; DAS28-ESR, Disease Activity Score in 28 joints-Erythrocyte Sedimentation Rate; FAS, full analysis set.
非 KM Figure
Figure 3Figure 3 Serum drug concentration from baseline to week 52 in participants receiving RGB-19 or tocilizumab (PK analysis set). PK, pharmacokinetics.
非 KM Figure